XML 112 R84.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMON STOCK: Common Stock Narrative (Details)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
shares
Dec. 31, 2021
shares
Class of Stock [Line Items]      
Shares granted (in shares) 75,295 73,131 76,147
Shares issued during the year 53,345 45,413 54,594
Registered Public Offering, Initial Common Shares Offered 2,801,724    
Registered Public Offering, Price Per Share | $ / shares $ 92.80    
Registered Public Offering, Issuance Amount | $ $ 260,000    
Initial Forward Sale Price, Per Share | $ / shares $ 90.016    
Common Shares To Deliver To Settle Forward Sales Agreement, Gross 3,221,982    
Cash Received On Settlement Of Forward Sale Agreement | $ $ 291,900    
Cash To Deliver To Settle Forward Sales Agreement, Net | $ $ 23,900    
Common Shares To Deliver To Settle Forward Sales Agreement, Net 200,000    
Effect of Dilutive Securities (in shares) 89,000 [1] 41,000 46,000
Registered Public Offering, Initial Common Shares Offered, Greenshoe 420,258    
Registered Public Offering, Initial Common Shares Offered, Total 3,221,982    
Registered Public Offering, Issuance Amount, Greenshoe | $ $ 39,000    
Incremental CommonShares Attributable To Share Based Payment Arrangements, Forward Sale Agreement 34,131    
IDACORP      
Class of Stock [Line Items]      
Maximum leverage ratio requirement 0.65    
Leverage ratio 0.50    
Amount dividends were limited to based on covenant restrictions | $ $ 1,400,000    
Idaho Power Company      
Class of Stock [Line Items]      
Leverage ratio 0.51    
Amount dividends were limited to based on covenant restrictions | $ $ 1,200,000    
Percentage of capital threshold below which Idaho Power will not pay dividends to IDACORP 0.35    
Equity Capital Ratio 0.50    
Shares of preferred stock outstanding 0    
[1] The effect of dilutive securities amount includes 34,131 incremental shares related to FSAs as of December 31, 2023. See Note 6 - "Common Stock" for additional information concerning IDACORP's FSAs.